SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
MolecularMD Submits Premarketing Approval Application to the FDA for Its BCR-ABL T315I Mutation Test, a Companion Diagnostic to Ponatinib, an Investigational BCR-ABL Inhibitor